

# Joyxit<sup>®</sup>

Flupentixol & Melitracen

## COMPOSITION:

Joyxit<sup>®</sup> Tablet: Each film coated tablet contains Flupentixol BP 0.5 mg & Melitracen INN 10 mg.

## PHARMACOLOGY:

Maximal serum concentration is reached in about 4 hours after oral administration of flupentixol and about 4 hours after oral administration of melitracen. The biological half-life of flupentixol is about 35 hours and that of melitracen is about 19 hours. The combination of flupentixol and melitracen does not seem to influence the pharmacokinetic properties of the individual compounds.

## INDICATION:

Anxiety, depression, asthenia, psychogenic depression, depressive neuroses, masked depression, long lasting myogenic headache, migraine, gastrointestinal disturbances without organic findings, psychosomatic affections accompanied by anxiety and apathy, menopausal depression, dysphoria and depression in alcoholics and drug-addicts.

## DOSE & ADMINISTRATION:

Adults: Usually 2 tablets daily (morning and noon). In severe cases the morning dose may be increased to 2 tablets.

Elderly: 1 tablet in the morning. Maintenance dose: Usually 1 tablet in the morning. In cases of insomnia or severe restlessness, additional treatment with sedative in the acute phase is recommended.

## CONTRA-INDICATION:

This combination is contraindicated to the patients with immediate recovery phase after myocardial infarction; defects in bundle-branch condition; untreated narrow angle glaucoma; acute alcohol, barbiturate and opiate intoxications; illnesses of the prostate with remainder urine formation; heavy liver and kidney damage. Joyxit should not be given to patients who have received a MAO-inhibitor within two weeks. Not recommended for excitable or overactive patients since its activating effect may lead to exaggeration of these characteristics.

## WARNING AND PRECAUTION:

If previously the patient has been treated with tranquilizers with sedative effect these should be withdrawn gradually.

## SIDE EFFECTS:

Side effects are rare, but could be transient restlessness and insomnia.

## USE IN PREGNANCY & LACTATION:

Joyxit<sup>®</sup> should preferably not be given during pregnancy and lactation.

## USE IN CHILDREN & ADOLESCENTS:

Joyxit<sup>®</sup> not recommended in children.

## DRUG INTERACTION:

Joyxit<sup>®</sup> may enhance the response to alcohol, barbiturates and other CNS depressants. Simultaneous administration of MAO-inhibitors may cause hypertensive crisis. Neuroleptics and thymoleptics reduce the antihypertensive effect of guanethidine and similar acting compounds and thymoleptics enhance the effects of adrenaline and noradrenaline.

## OVERDOSE:

In cases of overdosage the symptoms of intoxications by melitracen, especially of anticholinergic nature, dominate. More rarely extrapyramidal symptoms due to flupentixol occur.

## STORAGE:

Store in a dry and cool place below 30° C temperature and keep away from light and moisture. Keep out of reach of children.

## PACKING:

Joyxit<sup>®</sup> Tablet: Each box contains 5 x 10's Tablets in Alu-PVC blister pack.



Manufactured by

**Team Pharmaceuticals Ltd.**

B 75-79, BSCIC, Rajshahi, Bangladesh

IST-0070